Harvard Apparatus Regenerative Tech Inc. (HRGN)

[hondobud]

Ok just my view of how the CC went from reading transcript.(IMO)

https://seekingalpha.com/article/4098693-biostages-bstg-ceo-jim-mcgorry-q2-2017-results-earnings-call-transcript?page=4

We recently announced a financing arrangement with First Pecos LLC, including a $3 million private placement, the commitment by First Pecos to back up to two subsequent rights offering to raise additional proceeds of up to $14 million over the next two years.
Well the warrants are priced at .315 and the dilution is about 10M shares first tranche. So may be that's why the PPS is at .315

the Pediatric Atresia program meets our strategic goals. As such, we're now focusing on the pediatric program in favor of the previous plan to file an IND into Q3 for the adult indication.
Well they changed their mind and now not filing an IND and perusing pediatric implants. IMO this is a wash, FDA filing time to start down ped road for money incentives later. For those expecting the adult IND happening soon, a let down.

A few weeks ago we received a PR of the first esophagus implant and I was expecting a good update. Then we hear this at the CC:
This patient is now alive over three months after the surgery. The patient was affected by a cancer that require removal of a portion of his lung, removal and reconstruction of a part of his heart, and removal of a fragment on top of those in the chest.
So good luck to this patient, but what was their thinking when picking this probable terminal patient for the first esophagus implant ?

This?

there have been some warrant exercises with the recent higher price with people came into money. Notice they do not say how many warrants converted. These warrant exercises happened after the news release which stated an esophagus had been implanted, but nothing else was disclosed.


So there is a lot of positive spin about upcoming events and breakthroughs, BUT the PPS has to absorb the warrant exercises plus the new private placement in short order.

The company has money promised to continue into 2019, but the SP needs to be much higher so as not to bloat the OS count more than
necessary with the 14 million dollars still available to borrow in the placement with Pecos.

I like the premise of growing replacement body parts. I wonder can the company deliver good results quickly and how fast can they move to get the FDA's priority review for Pediatric Atresia.
That IMO, would be the next potential catalysts.